##semicolon##
толщина эпикардиального жира, ишемическая болезнь сердца, ингибиторы натрий глюкозного котранспортера 2, метаболический синдром, фенофибрат##submission.citations##
Драпкина О. М., Ивашкин В.Т. Абдоминальный болевойсиндром. Российский Журнал Гастроэнтерологии, Гепатологии, Колопроктологии 2002;12(4):8–153.
Мустафина И.А., Ионин В.А., Долганов А.А., Ишметов В.Ш., Пушкарева А.Э., Ягудин Т.А., Данилко К.В.,Загидуллин Н.Ш. Роль эпикардиальной жировой ткани в развитии сердечно-сосудистых заболеваний. Российский кардиологический журнал 2022;27(1S):4872, doi=10.15829/1560-4071-2022-4872
Bornachea O, Vea A, Llorente-Cortes V. Interplay between epicardial adipose tissue, metabolic and cardiovascular diseases. Clin Investig Arterioscler. 2018;30(5):230-239. (In English, Spanish). https://doi.org/ 10.1016/j.arteri.2018.03.003
Braha A, Timar B, Diaconu L, Lupusoru R, Vasiluta L, Sima A, Vlad A, Munteanu M, Albai A, Cipu D, Timar R. Dynamics of Epicardiac Fat and Heart Function in Type 2 Diabetic Patients Initiated with SGLT-2 Inhibitors. Diabetes Metab Syndr Obes. 2019; 12: 2559-2566 https://doi.org/10.2147/DMSO.S 223629
Brook, Robert D.Obesity, weight loss, and vascular function, Endocrine, 2006, 29, 01, 21–254.
Cinti F, Leccisotti L, Sorice GP, Capece U, D'Amario D, Lorusso M, Gugliandolo S, Morciano C, Guarneri A, Guzzardi MA, Mezza T, Capotosti A, Indovina L, Ferraro PM, Iozzo P, Crea F, Giordano A, Giaccari A. Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes. Cardiovasc Diabetol. 2023 Dec 19;22(1):349. doi: 10.1186/s12933-023-02091-0. PMID: 38115004; PMCID: PMC10731727.
Dönmez Y, Bulut A. Epicardial fat thickness is signifi cantly increased and related to LDL cholesterol level in patients with familial hypercholesterolemia. J Ultrasound. 2019;22(3): 309-314. https://doi.org/10.100 7/s40477-019-00368-3
Finer N. Medical consequences of obesity. Medicine. 2015; 43:88–93.
Forouzandeh, F. and Chang, S. M. and Muhyieddeen, K. andothers, Does quantifying epicardial and intrathoracic fat with noncontrast computed tomography improve risk-stratification beyond calcium scoring alone? Circulation: Cardiovascular Imaging, 2013, 60 1, 58-66, 10.1161/CIRCIMAGING.112.976316
Frühbeck G, Toplak H, Woodward E, Yumuk V, Maislos M, Oppert JM. Obesity: the gateway to ill health – an EASO position statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts. 2013; 6:117–120. doi: 10.1159/000350627.
Iacobellis, G. andWillens, H. J. Echocardiographic epicardial fat: a review of research and clinical applications, Journal of the American Society of Echocardiography, 2009, 22, 012, 1311–1319, 10.1016/j.echo.2009.10. 013
Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 2008; 32:1431–1437. doi: 10.1038/ijo.2008.102.
Kristiansen O.P., Nolsøe R.L., Larsen L., et al. Association of a functional 17b-estradiol sensitive IL6-174G/C promoter polymorphism with early-onset type 1 diabetes in females. Human Molecular Genetics. 2003; 12 (10): 1101–1110. doi: 10.1093/hmg/ ddg132
Mohlig M., Boeing H., Spranger J., et al. Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes. J. Clin. Endocr. Metab. 20 04; 89: 1885-1890. doi: 10.1210/jc.2003-031 101.
Tsao, H-M and Hu, W-C and Wu, M-Hand others, Quantitative analysis of quantity and distribution of epicardial adipose tissue surrounding the left atrium inpatients with atrial fibrillation and effect of recurrence after ablation American Journal of Cardiology, 2011, 107, 010, 1498–1503, 10.1016/j.amjcard.2011.01.027, https://doi.org/10.1016/ j.amjcard.2011.01.027
Rostamzadeh, A. and Khademvatani, K. and Seyed Mohammadzadeh, M. H. and others, Association of epicardial fat thickness assessed by echocardiography with the severity of coronary arterydisease, Journal of Cardiovascular and Thoracic Research, 2020, 12, 02, 114-119, 10.34172/jcvtr.2020.19
Song XT, Wei YL, Rui YF, Fan L. Echocardiographic evaluation of the effect of dapagliflozin on epicardial adipose tissue and left ventricular systolic function in type 2 diabetes mellitus. J Diabetes Complications. 2023 Jul;37(7):108509. doi: 10.1016/j.jdiacomp.2 023.108509. Epub 2023 May 18. PMID: 3723 5925.
Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, Adamo K, Alberga A, Bell R, Boulé N, Boyling E, Brown J, Calam B, Clarke C, Crowshoe L, Divalentino D, Forhan M, Freedhoff Y, Gagner M, Glazer S, Grand C, Green M, Hahn M, Hawa R, Henderson R, Hong D, Hung P, Janssen I, Jacklin K, Johnson-Stoklossa C, Kemp A, Kirk S, Kuk J, Langlois MF, Lear S, McInnes A, Macklin D, Naji L, Manjoo P, Morin MP, Nerenberg K, Patton I, Pedersen S, Pereira L, Piccinini-Vallis H, Poddar M, Poirier P, Prud'homme D, Salas XR, Rueda-Clausen C, Russell-Mayhew S, Shiau J, Sherifali D, Sievenpiper J, Sockalingam S, Taylor V, Toth E, Twells L, Tytus R, Walji S, Walker L, Wicklum S. Obesity in adults: a clinical practice guideline. CMAJ. 2020 Aug 4;192(31): E875-E891. doi: 10.1503/cmaj.191707. PM ID: 32753461; PMCID: PMC7828878.
World Health Organization. WHO fact sheets No 311. Geneva: WHO; 2015. Obesity and Overweight. www.who.int/mediacentre/ factsheets / fs311 / en / (last accessed November 30, 2015).
World Health Organization. World Health Statistics 2015. Geneva: WHO; 2015. pp. 101–111. www.who.int/gho/publications/world_health_statistics/2015/en/ (last accessed November 30, 2015).